Screen paywalled articles pay only for those worth it. No subscriptions needed.

FiltRead's AI helps you decide if paywalled articles are worth reading and lets you purchase them for as little as $0.03.

How FiltRead scores articles: We analyze public metadata — title, topic, and structure. FiltRead does not access or reproduce paywalled content. You still pay to unlock.
Add to Chrome See how it works ↓
No subscription required Preload as little as $5 From $0.03/article
nytimes.com/science/mrna-vaccine-pancreatic-cancer
The New York Times · Science · Research
New mRNA Trial Shows 94% Reduction in Pancreatic Cancer Recurrence
A landmark clinical trial conducted across 14 medical centers has demonstrated that a personalized mRNA vaccine, when combined with standard chemotherapy, reduced pancreatic cancer recurrence by 94% over an 18-month follow-up period. The study, published in Nature Medicine, enrolled 260 patients with resected pancreatic ductal adenocarcinoma...
🔒 Subscriber content — article locked
SIGNAL SCORE
8.7 /10
Worth It
AI SUMMARY
Landmark mRNA vaccine trial shows 94% reduction in pancreatic cancer recurrence across 14 medical centers. Published in Nature Medicine with 260 patients enrolled.
Unlock price $0.10
47 SCORED TODAY · 7 UNLOCKED · $0.63 SPENT
The Signal Score

One number.
Better decisions.

FiltRead evaluates depth, source credibility, originality, and relevance to your reading habits — distilled into a single score so you can decide in seconds.

1–3
Skip it
4–6
Your call
7–8
Worth reading
9–10
Don't miss it
Financial Times · Markets Not Subscribed
Federal Reserve Signals Two Rate Cuts in 2026 as Inflation Nears Target
9.1 /10
Don't Miss It
High
Depth
9.4
Credibility
High
Originality
Med
Relevance
The Federal Reserve's latest dot plot indicates two quarter-point rate cuts expected in the second half of 2026, as core PCE inflation tracks toward the 2% target. Markets initially rallied on the dovish signal before tempering gains...
How It Works

Read smarter.
Pay only for what matters.

The average reader pays $400/year across subscriptions they barely use. FiltRead charges only for what you unlock.

Step 01
🔒Paywall detected
The moment you hit a paywall, FiltRead's AI detects it and begins analyzing the article's topic, publication, and structure using publicly available signals. The article content remains locked.
Step 02
📊Signal score appears
A Signal Score from 1–10 appears alongside a plain-language AI summary. High signal means depth, credibility, and relevance. Low signal means skip it — no money spent, paywall still intact.
Step 03
⚡You decide
Score is high? One tap unlocks the full article for cents from your preloaded wallet. Score is low? Skip and move on — you've spent nothing. You control every unlock, every time.
Pricing

Pay per article.
Not per month.

Prices are set by publication tier. You see the exact price before you unlock — always.

Long-form & Investigative
$0.10 — $0.20
In-depth reporting, longform research, investigative journalism, and analysis.
News & Commentary
$0.06 — $0.12
Breaking news, opinion, features.
Blogs & Independent
$0.03 — $0.08
Newsletters, independent writers, Substack.
Universal wallet. Preload $5 and unlock 25–60 articles across every publication. No expiry.
FAQ

Common questions.

No. FiltRead scores articles using publicly available metadata — title, publication, topic, and structure. The article content remains locked until you choose to pay. FiltRead does not access, store, or reproduce paywalled content in any form. You still pay the publication to unlock.
Your wallet balance is stored securely and never expires. You can top it up at any time via Stripe. Unused balance rolls over indefinitely.
FiltRead works on NYT, WSJ, Bloomberg, The Atlantic, STAT News, Wired, The Economist, The New Yorker, Financial Times, TechCrunch and more. We add new publications regularly.
Yes. FiltRead does not track or store which articles you read. Your wallet is pseudonymous and your reading stays yours.